Cancer in America
Earlier this year, the American Cancer Society released the latest figures on the state of the nation's battle against the world's most dreaded disease. The good news is that cancer death rates are down across the board. The not-so-good news is that less educated Americans are dying prematurely in greater numbers.
Better Way to Diagnose Cancer Sooner
The main reason pancreatic cancer is one of the hardest to treat is because it's usually diagnosed so late. There are currently no early screening tools, but that may soon change.
FDA approves new treatment for rare type of pancreatic cancer
On Thursday, the U.S. Food and Drug Administration (FDA) approved Afinitor ( everolimus ) to treat patients with progressive neuroendocrine tumors located in the pancreas ( PNET ) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).
FDA Approves Drug for Advanced Pancreatic Cancer
Basel, May 5, 2011 - Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.
Aspirin May Decrease Pancreatic Cancer
Taking aspirin at least once a month significantly lowers the risk of developing cancer of the pancreas.
Diabetes Increases Risks of Cancer
A new study shows that avoiding or controlling diabetes may reduce risks of developing or dying from cancer.
Discovery Holds Hope for Pancreatic and Breast Cancer
Recent research has uncovered a protein implicated in both pancreatic and breast cancer tumors.
Clinical Trial for Sutent Stopped
A phase-3 clinical trial studying the effects of Sutent (sunitinib) has been halted early as the drug is shown to be effective in treating advanced pancreatic islet cell tumors.
A Closer Look at a Killer
New research from Johns Hopkins University suggests why some people with a rare pancreatic cancer are able to live for a decade or longer from diagnosis.